The investigation of antimicrobial peptides expression and its related interaction with methotrexate treatment in patients with psoriasis vulgaris. (2nd October 2017)

• Record Type: Journal Article
• Authors: Ozlu, Emin; Karadag, Ayse Serap; Ozkanli, Seyma; Oguztuzun, Serpil; Akbulak, Ozge; Uzuncakmak, Tugba Kevser; Demirkan, Serkan; Akdeniz, Necmettin
• Is Part Of: Cutaneous and ocular toxicology. Volume 36:Number 4(2017)
• Page Start: 321
• Page End: 326
• Publication Date: 2017-10-02
• Subjects: Antimicrobial peptides -- methotrexate -- psoriasis; Dermatotoxicology -- Periodicals; Ocular toxicology -- Periodicals; Ocular pharmacology -- Periodicals; Dermatopharmacology -- Periodicals; Toxicology -- Periodicals; 615.9
• DOI: 10.1080/15569527.2016.1277430
• Languages: English
• ISSNs: 1556-9527

Abstract

Abstract: Background : Psoriasis is a chronic, inflammatory and immune-mediated disease. Recently, the role of antimicrobial peptides (AMPs) such as human beta defensins (hBDs) in the pathogenesis of psoriasis has been investigated. We aimed to evaluate the expression profiles of hBD-1 and hBD-2 in psoriatic skin before and after methotrexate (MTX) therapy and to compare healthy controls. Methods : Immunohistochemical expressions of hBD-1 and hBD-2 were assessed in 16 patients with psoriasis vulgaris and 20 normal skin biopsies from healthy controls. The patients were administered a 12 week of MTX and skin biopsy samples were obtained from the lesional skin of the patients pre-/posttreatment and normal body of the healthy controls. Results : The median (range) Psoriasis Area and Severity Index (PASI) value was 21.6 (8.2–27.7) before the treatment whereas; 3.05 (1–23.4) after the treatment. hBD-1 expression in psoriasis patients was significantly higher as compared to the healthy controls before treatment ( p < 0.01). No significant difference was observed between psoriasis patients and healthy controls in terms of hBD-2 expression before treatment ( p > 0.05). No significant difference was observed between before–after MTX treatment in terms of hBD-1 and hBD-2 expression levels in psoriasis patients ( p > 0.05). Conclusions : These findings suggest a role for hBD-1 in psoriasis pathogenesis. But MTX treatment does not affect on hBD-1 and hBD-2 expressions. Further studies are needed to assess the roles of these AMPs in psoriasis etiopathogenesis.